Gilead Sciences, Inc.

Laurent P Debien

Adam James Schrier

James G Taylor

Hyung-Jung Pyun

Eda Y Canales

Petr Jansa

Michael Sangi

Roland D Saito

Joshua J Van Veldhuizen

Jennifer Alissa Loyer-Drew

Marina Shatskikh

Lianhong Xu

Jennifer Anne Treiberg

Rick Andrew Lee

Stephane Perreault

Daniel H Byun

Gary Bruce Phillips

Zheng-Yu Yang

Michael L Mitchell

Gregory Notte

Richard Y Huang

Elbert Chin

Chienhung Chou

Ryan McFadden

Zhenhong R Cai

Chao-I Hung

Prasenjit Kumar Mukherjee

Yifan Deng

Weng K Chang

Megan K Armstrong

Shaina V Nguyen

Joshua D Farr

Daniel Roa

Pancham Lal Gupta

Katie A Spence

Benjamin J June

Timothy R Hansen

Luisruben P Martinez

The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.

PRMT5 inhibitors and uses thereof

The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Inhibitors of peptidylarginine deiminases

Growing community of inventors

San Francisco, CA, United States of America

Laurent P Debien